Provention Bio Overview
Latest P/E ratio for Provention Bio: -16.43 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-16.43
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Provention Bio (PRVB) currently reports a P/E ratio of -16.43. That is below the Healthcare sector average of 19.01. Use the charts on this page to explore Provention Bio's P/E ratio history and peer comparisons.
Provention Bio's P/E ratio of -16.43 is lower than the Healthcare sector average of 19.01. That is roughly 186.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Provention Bio's market price to a fundamental measure such as earnings, sales, or book value. At -16.43, PRVB can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -16.43, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.01. From there, open related valuation or income-statement pages for Provention Bio, and consider following PRVB for alerts when major investors trade the stock.
Provention Bio is classified in the Healthcare sector. On P/E ratio, it currently shows -16.43 versus a sector average near 19.01. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRVB with unrelated industries.
